Evolent Health Inc (EVH) Receives $27.78 Consensus PT from Analysts

Evolent Health Inc (NYSE:EVH) has been given an average recommendation of “Buy” by the eighteen research firms that are currently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and fourteen have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $27.78.

Several brokerages recently weighed in on EVH. Zacks Investment Research upgraded Evolent Health from a “sell” rating to a “hold” rating in a research note on Monday, October 9th. SunTrust Banks restated a “buy” rating and issued a $30.00 price target on shares of Evolent Health in a research note on Wednesday, September 20th. Citigroup began coverage on Evolent Health in a research note on Thursday. They issued a “buy” rating for the company. Robert W. Baird restated an “outperform” rating and issued a $25.00 price target (down previously from $35.00) on shares of Evolent Health in a research note on Tuesday, September 26th. They noted that the move was a valuation call. Finally, Canaccord Genuity restated a “buy” rating and issued a $32.00 price target on shares of Evolent Health in a research note on Friday, October 6th.

Evolent Health (EVH) traded down $0.30 during midday trading on Tuesday, hitting $12.95. The company’s stock had a trading volume of 637,673 shares, compared to its average volume of 1,530,000. The stock has a market cap of $1,000.00 and a price-to-earnings ratio of -11.36. Evolent Health has a twelve month low of $10.30 and a twelve month high of $27.50. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.34 and a quick ratio of 3.34.

Evolent Health (NYSE:EVH) last released its quarterly earnings data on Thursday, November 2nd. The technology company reported ($0.04) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.08) by $0.04. Evolent Health had a negative return on equity of 5.05% and a negative net margin of 15.86%. The business had revenue of $107.90 million during the quarter, compared to analyst estimates of $104.49 million. During the same quarter last year, the business posted ($0.26) EPS. The company’s revenue was up 79.2% on a year-over-year basis. sell-side analysts expect that Evolent Health will post -0.57 earnings per share for the current year.

Large investors have recently bought and sold shares of the business. JPMorgan Chase & Co. increased its stake in Evolent Health by 7.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 5,438,126 shares of the technology company’s stock worth $137,857,000 after buying an additional 379,185 shares in the last quarter. Stifel Financial Corp acquired a new position in shares of Evolent Health during the 2nd quarter worth approximately $425,000. Kornitzer Capital Management Inc. KS acquired a new position in shares of Evolent Health during the 3rd quarter worth approximately $14,258,000. Edmond DE Rothschild Holding S.A. boosted its holdings in shares of Evolent Health by 6.9% during the 2nd quarter. Edmond DE Rothschild Holding S.A. now owns 387,000 shares of the technology company’s stock worth $9,810,000 after purchasing an additional 25,000 shares during the last quarter. Finally, Alyeska Investment Group L.P. boosted its holdings in shares of Evolent Health by 393.1% during the 3rd quarter. Alyeska Investment Group L.P. now owns 250,000 shares of the technology company’s stock worth $4,450,000 after purchasing an additional 199,300 shares during the last quarter. Institutional investors own 95.38% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Evolent Health Inc (EVH) Receives $27.78 Consensus PT from Analysts” was originally published by Transcript Daily and is owned by of Transcript Daily. If you are accessing this article on another domain, it was stolen and republished in violation of US & international copyright law. The correct version of this article can be viewed at https://transcriptdaily.com/2018/01/06/evolent-health-inc-evh-receives-27-78-consensus-pt-from-analysts.html.

Evolent Health Company Profile

Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.

Analyst Recommendations for Evolent Health (NYSE:EVH)

Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply